Clinical Trial Update: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and efficacy of selonsertib, firsocostat, and cilofexor in adults with nonalcoholic steatohepatitis (NASH) and NAF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cilofexor (cilofexor)
• Firsocostat (firsocostat)
• Selonsertib (selonsertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED | Results posted: 2022-02-02